share_log

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6

Moomoo 24/7 ·  Apr 2 08:40

HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $10 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment